Results 141 to 150 of about 826,950 (244)

Instrumental activities of daily living in older adults with epilepsy: A cross‐sectional and longitudinal multicenter study

open access: yesEpilepsia, EarlyView.
Abstract Objective Instrumental activities of daily living (IADLs) represent a critical but understudied measure of day‐to‐day function in people with epilepsy (PWE). In the multicenter Brain Aging and Cognition in Epilepsy (BrACE) study of PWE ≥55 years of age, we examined the proportion, clinical correlates, epilepsy‐related predictors, and ...
Ifrah Zawar   +17 more
wiley   +1 more source

Predicting levetiracetam neuropsychiatric adverse effects using graph‐theoretical electroencephalographic network metrics in drug‐naive focal epilepsy: A multicenter longitudinal study

open access: yesEpilepsia, EarlyView.
Abstract Objective Levetiracetam (LEV) is an antiseizure medication approved for focal and generalized epilepsy. Despite its efficacy, neuropsychiatric adverse effects (NP‐AEs) may lead to treatment discontinuation. Quantitative electroencephalographic (qEEG) graph‐theoretical analysis has emerged as a valuable tool for identifying neurophysiological ...
Marco Sferruzzi   +10 more
wiley   +1 more source

Prevalence of epilepsy and the burden of underlying causes: Canadian validation of Danish estimates

open access: yesEpilepsia, EarlyView.
Abstract Objective Recent work has provided population‐based estimates of the prevalence of cause‐specific epilepsy across the lifespan in Denmark. We sought to externally validate these Danish “secondary epilepsy” findings to ascertain consistency across geographic regions.
Marin Anderson   +6 more
wiley   +1 more source

Beyond seizure control: Non–seizure‐related outcomes in focal‐onset epilepsy treated with adjunctive cenobamate. Third interim results from the BLESS study

open access: yesEpilepsia, EarlyView.
Abstract Objective Cenobamate is approved for treatment of focal seizures in adults, but evidence on non‐seizure outcomes remains limited. This interim statistical analysis of the cenoBamate in aduLts with focal‐onsEt SeizureS (BLESS) study evaluated patient‐ and clinician‐reported outcomes for up to 52 weeks of cenobamate treatment.
Simona Lattanzi   +206 more
wiley   +1 more source

Home - About - Disclaimer - Privacy